Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) ~~The use of~~ A method for inducing immunity against tumor in a patient, comprising administering to the patient in a time-staggered manner: (1) autologous tumor cells or allogenic tumor cells of the same tumor type each treated to prevent their survival after reinfusion; and (2) ~~in a time-staggered application with~~ intact bispecific and/or trispecific antibodies having the following properties of:

(a) binding to a T cell;

(b) binding to at least one antigen on a tumor cell; and

(c) binding via their Fc portion (in the case of bispecific antibodies) or via a third specificity (in the case of trispecific antibodies) to Fc receptor-positive cells~~;~~

~~wherein the tumor cells and the intact antibodies directed against the tumor cells are administered in a time-staggered manner to the human or the animal to be immunized to achieve an immunization against the tumor~~.

2. (Currently amended) The ~~use~~ method according to claim 1 wherein the administration of said tumor cells ~~are administered~~ is prior to or after the ~~antibodies or~~ administration of said antibodies ~~are administered prior to the tumor cells wherein~~ and the interval between ~~each~~ the ~~administration~~ administrations is 1 - 48 hours.

3. (Currently amended) The ~~use~~ method according to claim 1 wherein the interval is 1 - 24 hours~~, preferably 1 - 12 hours, further preferred 1 - 6 hours or 1 - 4 hours or 2 - 4 hours~~.

4. (Currently amended) The ~~use~~ method according to claim 1 wherein the antibodies are administered in an amount~~, each based on one infusion,~~ of about 5 - 500 μg, ~~preferably 10 - 300 μg, further preferred 1 - 100 μg or 10 - 50 μg, and the tumor cells are~~

~~administered in an amount, each based on one infusion, of 10^7 – 10^9 cells, preferably about 10^8 cells~~ in each infusion.

5. (Currently amended) The ~~use~~ method according to claim 1 wherein said ~~antibodies are selected to be capable of binding, via their Fc portion in the case of bispecific antibodies or via their specific binding arm in the case of trispecific antibodies to~~ Fc receptor-positive cells ~~having~~ have an Fcγ receptor I, II, or III.

6. (Currently amended) The ~~use~~ method according to claim 5 wherein said antibodies are able to bind to monocytes, makrophages, dendritic cells, "natural killer" cells (NK cells) and/or activated neutrophils being Fcγ receptor I-positive cells.

7. (Currently amended) The ~~use~~ method according to claim 1 wherein said antibodies are capable of inducing tumor-reactive complement-binding antibodies and therefore of inducing a humoral immune response.

8. (Currently amended) The ~~use~~ method according to claim 1 wherein said antibodies are selected to bind to the T cells via CD2, CD3, CD4, CD5, CD6, CD8, CD28, and/or CD44.

9. (Currently amended) The ~~use~~ method according to claim 1 wherein said antibodies are selected so that following their binding to the Fc receptor-positive cells the expression of CD40, CD80, CD86, ICAM-1, and/or LFA-3 being co-stimulatory antigens and/or the secretion of cytokins by the Fc receptor-positive cell is initiated or increased.

10. (Currently amended) The ~~use~~ method according to claim 9 wherein the antibodies are selected so that the secretion of IL-1, IL-2, IL-4, IL-6, IL-8, IL-12, INF-γ being cytokins and/or of TNF-α is increased.

11. (Currently amended) The ~~use~~ method according to claim 1 wherein said bispecific antibody is selected ~~to be~~ from the group consisting of an anti-CD3 X anti-tumor-associated antigen antibody, ~~and/or~~ anti-CD4 X anti-tumor-associated antigen antibody, ~~and/or~~

anti-CD5 X anti-tumor-associated antigen antibody, ~~and/or~~ anti-CD6 X anti-tumor-associated antigen antibody, ~~and/or~~ anti-CD8 X anti-tumor-associated antigen antibody, ~~and/or~~ anti-CD2 X anti-tumor-associated antigen antibody, ~~and/or~~ anti-CD28 X anti-tumor-associated antigen antibody, and ~~and/or~~ anti-CD44 X anti-tumor-associated antigen antibody.

12. (Currently amended) The ~~use~~ method according to claim 1 wherein said bispecific antibody is selected from one or more of the following combinations of isotypes:

rat-IgG2b/mouse-IgG2a,
rat-IgG2b/mouse-IgG2b,
rat-IgG2b/mouse-IgG3,

rat-IgG2b/human-IgG1,
rat-IgG2b/human-IgG2,
rat-IgG2b/human-IgG3[oriental allotype G3m(st) = binding to protein A],
rat-IgG2b/human-IgG4,

rat-IgG2b/rat-IgG2c,

mouse-IgG2a/human-IgG3[caucasian allotypes G3m(b+g) = no binding to protein A, in the following indicated as *]

mouse-IgG2a/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-
human-IgG3*-[CH2-CH3]

mouse-IgG2a/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human- IgG3*-[CH2-CH3]

mouse-IgG2a/human-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human- IgG3*-[CH2-CH3]

mouse-[VH-CH1,VL-CL]-human-IgG1/rat-[VH-CH1,VL-CL]-
human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-[VH-CH1,VL-CL]-human-IgG4/rat-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4[N-terminal region of CH2]-human- IgG3*[C-terminal region of CH2: > aa position 251]-human- IgG3*[CH3]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge-CH2-CH3]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG2-[hinge-CH2-CH3]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG3-[hinge-CH2-CH3, oriental allotype]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG4-[hinge-CH2-CH3]

human-IgG1/human-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG2[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG2[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG2/human-[VH-CH1,VL-CL]-human-IgG2-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG4/human-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG4/human-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

mouse-IgG2b/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-IgG2b/human-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-[VH-CH1,VL-CL]-human-IgG4/rat-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3]

human-IgG4/human-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3].

13. (Currently amended) The ~~use~~ method according to claim 1 wherein said ~~bispecific~~ antibody is ~~selected from~~ a heterologous bispecific or trispecific antibody~~, preferably for a heterologous rat/mouse bispecific antibody~~.

14. (Currently amended) The ~~use~~ method according to claim 1 wherein the trispecific antibody ~~has~~ comprises a T cell binding arm, a tumor cell binding arm and a third specificity for binding to Fc receptor-positive cells.

15. (Currently amended) The ~~use~~ method according to claim 14 wherein said trispecific antibody is selected ~~to be~~ from the group consisting of an anti-CD3 X anti-tumor-associated antigen antibody, ~~and/or~~ anti-CD4 X anti-tumor-associated antigen antibody, ~~and/or~~ anti-CD5 X anti-tumor-associated antigen antibody, ~~and/or~~ anti-CD6 X anti-tumor-associated

antigen antibody, ~~and/or~~ anti-CD8 X anti-tumor-associated antigen antibody, ~~and/or~~ anti-CD2 X anti-tumor-associated antigen antibody, ~~and/or~~ anti-CD28 X anti-tumor-associated antigen antibody, and ~~and/or~~ anti-CD44 X anti-tumor-associated antigen antibody.

16. (Currently amended) The ~~use~~ method according to claim 1 wherein tumor cells ~~are used which~~ have been treated by irradiation~~, preferably by gamma-irradiation, further preferred in a dose of 50 to 200 Gy,~~ or by a chemical substance ~~substances, preferably mitomycin C~~.

17. (Currently amended) The ~~use~~ method according to claim 1 wherein said antibody ~~is selected to bind~~ binds to a surface antigen ~~being the target antigen~~ on ~~the target cell~~ said tumor cells, wherein said surface antigen ~~which~~ is inducible and ~~which~~ is absent ~~form~~ from ~~the target cell~~ said tumor cells in the uninduced state (normal state) or is present in an amount ~~which is so low that the number is~~ insufficient for destruction of ~~the target cell~~ said tumor cells by the antibody.

18. (Currently amended) The ~~use~~ method according to claim 17 wherein the tumor cells are subjected to a heat pretreatment to increase the immunogenicity.

19. (Currently amended) The ~~use~~ method according to claim 17 wherein the inducible antigen is heat shock proteins or MHC class I-related MIC molecules ~~are employed as the inducible antigens~~.

20. (Currently amended) The ~~use~~ method according to claim ~~17~~ 19 wherein the heat shock proteins are HSP25, Hsp60 or Hsp70 (Hsp72) or Hsp90 proteins ~~are used as heat shock proteins~~ and the MIC molecules are MIC A ~~and~~ or MIC B molecules ~~are used as MIC molecules~~.

21. (Currently amended) The ~~use~~ method according to claim 20 wherein ~~said antibody is directed against target~~ the inducible antigens which after induction of ~~the target cell~~ said tumor cells are present in an amount of at least 100 and at the most 500,000 per ~~target~~ tumor cell.

22. (Currently amended) The ~~use~~ method according to claim 21 wherein the antibody is ~~further selected to be~~ capable of activating Fc receptor-positive cells whereby the expression of cytokins and/or co-stimulatory antigens is initiated or increased.

23. (Currently amended) The ~~use~~ method according to claim 1 wherein the time-staggered application of the intact bispecific and/or trispecific antibodies is performed several times ~~to increase the success of the immunization~~.

24. (New) The method of claim 3, wherein the interval is 1-12 hours.

25. (New) The method of claim 24, wherein the interval is 1-6 hours.

26. (New) The method of claim 25, wherein the interval is 1-6 hours.

27. (New) The method of claim 26, wherein the interval is 2-4 hours.

28. (New) The method of claim 4, wherein the antibodies are administered in an amount of about 10-300 μg.

29. (New) The method of claim 28, wherein the antibodies are administered in an amount of about 10-100 μg.

30. (New) The method of claim 29, wherein the antibodies are administered in an amount of about 10-50 μg.

31. (New) The method of claim 4, wherein the tumor cells are administered in an amount of about 10^7 - 10^9 cells.

32. (New) The method of claim 31, wherein the tumor cells are administered in an amount of about 10^8 cells.

33. (New) The method of claim 13, wherein the heterologous bispecific antibody is a heterologous rat/mouse bispecific antibody.

34. (New) The method of claim 16, wherein the irradiation is gamma irradiation.

35. (New) The method of claim 16, wherein the irradiation has a dose of about 50 to 200 Gy.

36. (New) The method of claim 16, wherein the chemical substance is mitomycin C.